{"name":"Hôpital Necker-Enfants Malades","slug":"h-pital-necker-enfants-malades","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Béfizal","genericName":"Béfizal","slug":"b-fizal","indication":"Type 2 diabetes","status":"phase_2"}]}],"pipeline":[{"name":"Béfizal","genericName":"Béfizal","slug":"b-fizal","phase":"phase_2","mechanism":"Béfizal is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNTVp0QWd0X2Utd01NZE91dHM5UGhkLWZHazRvbGdqcnpuUlNySGt4cXJCZGVUTm9NR1g0NEJpcUV1dC1VaS1EdERqZ1Z2Nkg2aFpLYVU0UzVwU09oQjZNTlBiNUlNNTBKWTVqQ0tIZl9kNGplaGtxRE4tT3l1OXlRVg?oc=5","date":"2024-11-20","type":"pipeline","source":"pharmaphorum","summary":"Pfizer bags EU okay for haemophilia drug Hympavzi - pharmaphorum","headline":"Pfizer bags EU okay for haemophilia drug Hympavzi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1xQnlnbm9WbE1jUnhfM2VpVVlUUm1rQm42Xy1Zc1p3U2kyUVZ4Vlo3bV92R0s0X0RhZkJKdThGODljdlY0RnktMGcyNWlpZE15OVphWVBpNHZCdEhSdGZB?oc=5","date":"2024-06-17","type":"pipeline","source":"nature.com","summary":"Targeted therapy for capillary-venous malformations - nature.com","headline":"Targeted therapy for capillary-venous malformations","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9JQ1RaaDRJeDAyWXRMcFNEUGFXZlFnazZ1dHBBU2NfX2s1Uy1GVzh4cmZSNFJGMV82c1Ixd1NZMVRTX2xuTWo2Rm5ZV2tlSUVtNGlxT25DVWRFNTRZU0ZwVDdoNng3emlz?oc=5","date":"2022-06-20","type":"pipeline","source":"Wiley Online Library","summary":"Subcontracting sterile pediatric and adult chemotherapy preparations activity: A global risk analysis - Wiley Online Library","headline":"Subcontracting sterile pediatric and adult chemotherapy preparations activity: A global risk analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNOF9SbHdNSlkwT1ZzZEtBc2QtMjFkWWNwOWtJNXJUQzA4Qkwzamk2R25JTkFDNE9WREdGbmh2bnRhb3lFaURfaFVTX2JUTmFlSnA1aVRUY2FzU0lMdUhKMzFiOEdIZEZkb1Y1UW1ULVJyMDdkOHJObWxrX0gxcXdmTUFwcTBES0JHczNaQ0M5N25ycEwtTFN3WUlMcUNuNUVn?oc=5","date":"2022-01-26","type":"pipeline","source":"Rockefeller University Press","summary":"Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib | Journal of Experimental Medicine - Rockefeller University Press","headline":"Treatment of two infants with PIK3CA-related overgrowth spectrum by alpelisib | Journal of Experimental Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1UOXVkcF9xbmY3X0h3VUctbFZlZmRGY1BRTF8xVlJXY1NNUjd2MFFmYnl5RlBFN3VILVJuaUxCb2FwVEY1OUEycC0wTE9VSnZIM0loajd5aGNlYU1uanVobkU5YWktZGZlVUE?oc=5","date":"2020-08-06","type":"pipeline","source":"Wiley Online Library","summary":"Severe hypersensitivity reaction to etoposide phosphate: A case report - Wiley Online Library","headline":"Severe hypersensitivity reaction to etoposide phosphate: A case report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9GYUowdUhrSlVLZWRsNWdzeWVVSzRzWEhVclRPeE95SkMyM1owZUxlMjhVTGZTNmtHM09pbWoyLS04TXNvM0lubEx5VXRlbHFVM2RaRHVidHZuYUlNZnc?oc=5","date":"2020-01-16","type":"pipeline","source":"nature.com","summary":"Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1 - nature.com","headline":"Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPTFNCRm5Ed3pIQlJtSHI0WkxxeW5yQnQxSFRMc0VKVGNVNTlKSEhvZjZjQkNaQlRxaUwzMzAwd09EYm9kYWlkSHpkdUxXUmE0Qk9lZzFtUktSUlQ5MzZydmNiTU1DMm85M1UzNkF0V0J0bXZZVnpvUzlZUk1VdVI3clNEelhXYU4yazBsV2c3dTFmX09DRTFsZWo1RTh3ZmhpSjBlLTJlOUUtMzJBMGlOU0piSEFEM1d4bnFfeVBFTGxmMEZ6cVcyQXhzVEtwU0Q5Wmd0andMUzh4T09FZ2lYSjRISlpkbmpmamVR?oc=5","date":"2019-10-04","type":"pipeline","source":"European Medical Journal","summary":"Key Considerations in the Management of Inflammatory Bowel Disease: Interviews with Key Opinion Leaders - European Medical Journal","headline":"Key Considerations in the Management of Inflammatory Bowel Disease: Interviews with Key Opinion Leaders","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}